NCT03438877 is a NA clinical trial of Intensive dosage of PD in Peritoneal Dialysis, sponsored by Peking University First Hospital.

Who is sponsoring NCT03438877?

NCT03438877 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT03438877?

Interventions in NCT03438877: Intensive dosage of PD, Regular dosage of PD.

What condition does NCT03438877 study?

NCT03438877 studies Peritoneal Dialysis, Acute Kidney Injury.

Is NCT03438877 still recruiting?

NCT03438877 is currently terminated. Last updated 8 December 2021.

Last reviewed 2021-12-08 · How we verify

NCT03438877

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intensive Versus Regular Dosage For PD In AKI.

Terminated NA Last updated 8 December 2021

What this trial tests

NA trial testing Intensive dosage of PD in Peritoneal Dialysis in 6 participants. Terminated before completion.

Timeline

29 September 2018

Primary endpoint
26 December 2019

26 December 2019

Quick facts

Lead sponsor	Peking University First Hospital
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	29 September 2018
Primary completion	26 December 2019
Estimated completion	26 December 2019
Sites	7 locations across China

Drugs / interventions tested

Intensive dosage of PD
Regular dosage of PD

Conditions studied

Peritoneal Dialysis — all drugs for Peritoneal Dialysis →
Acute Kidney Injury — all drugs for Acute Kidney Injury →

Sponsor

Peking University First Hospital

Who can join

14 and older, any sex, with Peritoneal Dialysis or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, pilot RCT study, aiming to compare intensive dosage and regular dosage of PD for AKI patients with indications for dialysis. Aims of the study are to: Examine the feasibility of the study, which aims to determine the efficacy and safety of intensive PD dose for AKI patients as compared to regular PD dose. Establish the appropriate workflow for PD treatment for AKI patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Perioperative Acute Kidney Injury.
Gumbert SD, Kork F, Jackson ML, Vanga N, et al · · 2020 · cited 209× · PMID 31687986 · DOI 10.1097/aln.0000000000002968

Verify or expand the search:

Other recruiting trials for Peritoneal Dialysis

Currently open trials in the same condition.

NCT07098351 — Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis · NA · recruiting
NCT07077538 — Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients · NA · recruiting
NCT06876987 — The Mobile-based Training System in Peritoneal Dialysis Patients · NA · recruiting
NCT06641765 — Continuous Glucose Monitoring in Dialysis Patients With Diabetes · NA · active not recruiting
NCT06368713 — Exercise Improves Gastrointestinal Function in Peritoneal Dialysis Patients · NA · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03438877 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 8 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03438877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing